- Home
- JGH vs FHTX Comparison
JGH vs FHTX Comparison
Compare JGH & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JGH
- FHTX
- Stock Information
- Founded
- JGH 2014
- FHTX 2015
- Country
- JGH United States
- FHTX United States
- Employees
- JGH N/A
- FHTX N/A
- Industry
- JGH Investment Managers
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- JGH Finance
- FHTX Health Care
- Exchange
- JGH Nasdaq
- FHTX Nasdaq
- Market Cap
- JGH 304.1M
- FHTX 517.9M
- IPO Year
- JGH N/A
- FHTX 2020
- Fundamental
- Price
- JGH $12.97
- FHTX $7.55
- Analyst Decision
- JGH
- FHTX Strong Buy
- Analyst Count
- JGH 0
- FHTX 5
- Target Price
- JGH N/A
- FHTX $16.00
- AVG Volume (30 Days)
- JGH 73.9K
- FHTX 135.3K
- Earning Date
- JGH 01-01-0001
- FHTX 11-04-2024
- Dividend Yield
- JGH 9.85%
- FHTX N/A
- EPS Growth
- JGH N/A
- FHTX N/A
- EPS
- JGH N/A
- FHTX N/A
- Revenue
- JGH N/A
- FHTX $35,185,000.00
- Revenue This Year
- JGH N/A
- FHTX N/A
- Revenue Next Year
- JGH N/A
- FHTX $15.40
- P/E Ratio
- JGH N/A
- FHTX N/A
- Revenue Growth
- JGH N/A
- FHTX 61.95
- 52 Week Low
- JGH $10.36
- FHTX $2.70
- 52 Week High
- JGH $12.85
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- JGH 38.66
- FHTX 45.26
- Support Level
- JGH $12.99
- FHTX $7.24
- Resistance Level
- JGH $13.15
- FHTX $8.35
- Average True Range (ATR)
- JGH 0.11
- FHTX 0.54
- MACD
- JGH -0.05
- FHTX -0.06
- Stochastic Oscillator
- JGH 13.73
- FHTX 43.20
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.